---
document_datetime: 2023-09-21 18:00:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/omnitrope-epar-procedural-steps-taken-authorisation_en.pdf
document_name: omnitrope-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4088368
conversion_datetime: 2025-12-28 14:06:34.348399
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Sandoz GmbH submitted on  1 July 2004 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Omnitrope, through the centralised procedure under the legal base of Similar Biological Medicinal Product referring to Article 10.4 of Directive 2004/27/EC.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 1 July 2004.  The legal base for the application was Similar Biological Medicinal Product referring to Article 10.4 of Directive 2004/27/EC.
- The procedure started on 16 August 2004.
- The Rapporteur's first Assessment Report was circulated to all CHMP  members  on 29 October 2004.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 26 October 2004.
- During  the  meeting  on  13-16  December  2004,  the  CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 December 2004.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 4 February 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 24 March 2005.
- During  the  CHMP  meeting  on  18-21  April  2005, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP list of outstanding issues on 20 May 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 9 June 2005.
- The BWP during its meeting of 13-15 June 2005 adopted the BWP Report to be transmitted to the CHMP for endorsement.
- During  the  CHMP  meeting  on  20-23  June  2005,  the  CHMP  agreed  on  a  list  of  outstanding issues  (Following  assessment  of  responses  to  Day  180  List  of  Outstanding  Issues)  to  be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP list of outstanding issues on 1 July 2005.
- The BWP during its meeting of 18-20 July 2005 adopted the BWP Report to be transmitted to the CHMP for endorsement.
- During  the  CHMP  meeting  on  25-28  July  2005,  the  CHMP  discussed  the  responses  to  the outstanding issues.
- During  the  CHMP  meetings  of  September,  November  and  December  2005,  updates  were provided with regard to the responses to the outstanding issues.
- During January 2006, the outstanding issues were clarified in a satisfactory manner.
- During the meeting on 23-26 January 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Omnitrope on 26 January 2006.
- The applicant submitted a revised Letter of Undertaking, 23 January 2006.

Dr Frits Lekkerkerker

Co-Rapporteur: Dr Harald Enzmann